Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors

JAMA Oncol. 2018 Dec 1;4(12):1661-1662. doi: 10.1001/jamaoncol.2018.4316.

Authors

Daniel E Fein¹, Jessica K Paulus², Paul Mathew³

Affiliations

¹ Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
² Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.
³ Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts.

PMID: 30325997
DOI: 10.1001/jamaoncol.2018.4316

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / administration & dosage
Bleomycin / adverse effects
Choice Behavior
Cisplatin / administration & dosage*
Cisplatin / adverse effects
Dose-Response Relationship, Drug
Etoposide / administration & dosage*
Etoposide / adverse effects
Guideline Adherence / standards
Humans
Male
Neoplasm Metastasis
Neoplasms, Germ Cell and Embryonal / drug therapy*
Neoplasms, Germ Cell and Embryonal / mortality
Neoplasms, Germ Cell and Embryonal / pathology
Quality of Life
Standard of Care*
Survival Rate
Testicular Neoplasms / drug therapy*
Testicular Neoplasms / mortality
Testicular Neoplasms / pathology
Treatment Outcome

Substances

Bleomycin
Etoposide
Cisplatin